MP-101 is under clinical development by Mitochon Pharmaceuticals and currently in Phase I for Duchenne Muscular Dystrophy. According to GlobalData, Phase I drugs for Duchenne Muscular Dystrophy have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MP-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MP-101 overview

MP-101 is under development for the treatment of Huntington’s disease, optic neuritis, Duchenne muscular dystrophy (DMD), secondary progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS), amyotrophic lateral sclerosis, Alzheimer’s disease and Parkinson’s disease. It is a small molecule and administered orally. The drug candidate is a prodrug of dinitrophenol (DNP).

The drug candidate was also under development for the treatment of Battens disease, Rett syndrome  and burn victims and refractory epilepsy.

Mitochon Pharmaceuticals overview

Mitochon Pharmaceuticals (Mitochon Pharma) operates as a biotech company that develops drugs for neurodegenerative and neuromuscular diseases. The company’s pipeline products comprise mitochondrial modulators such as MP-101, MP-201 and MP-301. It targets diseases such as batten disease, stroke, huntington’s, duchenne muscular dystrophy, alzheimer’s, parkinson disease and severe burns. Mitochon Pharma’s MP101 preserves brain volume, medium spiny neurons and general neurons. The company also offers drugs for metabolic disorders due to over-nutrition such as diabetes, obesity and non-alcoholic steatohepatitis; and other diseases associated with high cellular stress. It undertakes clinical research to develop disease modifying therapies. Mitochon Pharma is headquartered in Whitpain, Pennsylvania, the US.

For a complete picture of MP-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.